Russell JA, et al. – A phase IIa trial investigated the initial pharmacodynamic effects, pharmacokinetics, and safety of selepressin in septic shock patients. Researchers reported that selepressin 2.5 ng/kg/minute rapidly replaced norepinephrine while maintaining adequate mean arterial pressure (MAP), and it possibly improves fluid balance and shortens the time of mechanical ventilation in septic shock patients.